6533b832fe1ef96bd129a417

RESEARCH PRODUCT

Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase

Amparo AraicoMaría Luisa FerrándizMaría Carmen TerencioJosé N. DomínguezC. LeónM. J. Alcaraz

subject

ChalconeNeutrophilsNitric OxideLeukotriene B4DinoprostoneGeneral Biochemistry Genetics and Molecular BiologyCell LineNitric oxideMiceStructure-Activity Relationshipchemistry.chemical_compoundChalconesmedicineAnimalsHumansCyclooxygenase InhibitorsLipoxygenase InhibitorsGeneral Pharmacology Toxicology and PharmaceuticsProstaglandin E2IC50Molecular StructurebiologySuperoxideMacrophagesElastaseGeneral MedicinechemistryBiochemistryCyclooxygenase 2MyeloperoxidaseArachidonate 5-lipoxygenasebiology.proteinmedicine.drug

description

Two series of phenylsulphonyl urenyl chalcone derivatives (UCH) with various patterns of substitution were tested for their effects on nitric oxide (NO) and prostaglandin E2 (PGE2) overproduction in RAW 264.7 macrophages. None of the tested compounds reduced NO production more than 50% at 10 microM but most of them inhibited the generation of PGE2 with IC50 values under the micromolar range. Me-UCH 1, Me-UCH 5, Me-UCH 9, Cl-UCH 1, and Cl-UCH 9 were selected to evaluate their influence on human leukocyte functions and eicosanoids generation. These derivatives selectively inhibited cyclo-oxygenase-2 (COX-2) activity in human monocytes being Me-UCH 5 the most potent (IC50 0.06 microM). Selected compounds also reduced leukotriene B4 synthesis in human neutrophils by a direct inhibition of 5-lipoxygenase (5-LO) activity, with IC50 values from 0.5 to 0.8 microM. In addition, lysosomal enzyme secretion, such as elastase or myeloperoxidase as well as superoxide generation in human neutrophils were also reduced in a similar range. Our findings indicate that UCH derivatives exert a dual inhibitory effect on COX-2/5-LO activity. The profile and potency of these compounds may have relevance for the modulation of the inflammatory and nociceptive responses with reduction of undesirable side-effects associated with NSAIDs.

https://doi.org/10.1016/j.lfs.2005.11.017